Advanced glycation end products and the kidney

被引:301
作者
Bohlender, JM [1 ]
Franke, S [1 ]
Stein, G [1 ]
Wolf, G [1 ]
机构
[1] Univ Klin Jena, Innere Med Klin 3, Dept Internal Med 3, Jena, Germany
关键词
RAGE; diabetic nephropathy; progression of renal disease; inflammation; glycoxidation;
D O I
10.1152/ajprenal.00398.2004
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Advanced glycation end products (AGEs) are a heterogeneous group of protein and lipids to which sugar residues are covalently bound. AGE formation is increased in situations with hyperglycemia ( e. g., diabetes mellitus) and is also stimulated by oxidative stress, for example in uremia. It appears that activation of the renin-angiotensin system may contribute to AGE formation through various mechanisms. Although AGEs could nonspecifically bind to basement membranes and modify their properties, they also induce specific cellular responses including the release of profibrogenic and proinflammatory cytokines by interacting with the receptor for AGE ( RAGE). However, additional receptors could bind AGEs, adding to the complexity of this system. The kidney is both: culprit and target of AGEs. A decrease in renal function increases circulating AGE concentrations by reduced clearance as well as increased formation. On the other hand, AGEs are involved in the structural changes of progressive nephropathies such as glomerulosclerosis, interstitial fibrosis, and tubular atrophy. These effects are most prominent in diabetic nephropathy, but they also contribute to renal pathophysiology in other nondiabetic renal diseases. Interference with AGE formation has therapeutic potential for preventing the progression of chronic renal diseases, as shown from data of animal experiments and, more recently, the first clinical trials.
引用
收藏
页码:F645 / F659
页数:15
相关论文
共 173 条
  • [1] ABEL M, 1995, NEPHROL DIAL TRANSPL, V10, P1662
  • [2] Oxidative stress in hypertension and chronic kidney disease: Role of angiotensin II
    Agarwal, R
    Campbell, RC
    Warnock, DG
    [J]. SEMINARS IN NEPHROLOGY, 2004, 24 (02) : 101 - 114
  • [3] Ahmed N, 2003, BIOCHEM SOC T, V31, P1417
  • [4] The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats
    Alderson, NL
    Chachich, ME
    Youssef, NN
    Beattie, RJ
    Nachtigal, M
    Thorpe, SR
    Baynes, JW
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (06) : 2123 - 2133
  • [5] Pyridoxamine: An extremely potent scavenger of 1,4-dicarbonyls
    Amarnath, V
    Amarnath, K
    Amarnath, K
    Davies, S
    Roberts, LJ
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (03) : 410 - 415
  • [6] Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein - A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation
    Anderson, MM
    Hazen, SL
    Hsu, FF
    Heinecke, JW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (03) : 424 - 432
  • [7] Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes
    Aronson, D
    [J]. JOURNAL OF HYPERTENSION, 2003, 21 (01) : 3 - 12
  • [8] S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE)
    Arumugam, T
    Simeone, DM
    Schmidt, AM
    Logsdon, CD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (07) : 5059 - 5065
  • [9] Renal proximal tubular metabolism of protein-linked pentosidine, an advanced glycation end product
    Asano, M
    Fujita, Y
    Ueda, Y
    Suzuki, D
    Miyato, T
    Sakai, H
    Saito, A
    [J]. NEPHRON, 2002, 91 (04): : 688 - 694
  • [10] Advanced glycation end-product cross-link breakers - A novel approach to cardiovascular pathologies related to the aging process
    Bakris, GL
    Bank, AJ
    Kass, DA
    Neutel, JM
    Preston, RA
    Oparil, S
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (12) : 23S - 30S